accountProactive Investors USA & Canada UPDATE 1-Acadia antipsychotic for Parkinson's succeeds in trial Reuters Nov 27 (Reuters) - An antipsychotic drug for Parkinson's disease patients being developed by Acadia Pharmaceuticals Inc succeeded in meeting the primary goal and key secondary goals of a pivotal late stage clinical trial, the company said on Tuesday. Acadia surges on Parkinson's psychosis...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Acadia antipsychotic for Parkinson's succeeds in trial - Reuters
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account